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The tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine
proteinase inhibitor. Recently, the aberrant methylation of TFPI-2
was detected frequently in pancreatic carcinoma (PCa) tissues but
not in normal pancreatic tissues. We analyzed the aberrant
methylation of TFPI-2 in the pure pancreatic juice (PPJ) aspirated
endoscopically from patients with various pancreatic diseases.
Using the highly sensitive methylation-specific polymerase chain
reaction (MSP) and quantitative MSP (Q-MSP) assay, we investigated
the aberrant methylation of TFPI-2 in nine human PCa cell lines and
in the PPJ from patients with PCa, intraductal papillary mucinous
neoplasms (IPMN) and chronic pancreatitis (CP). The incidence of
aberrant TFPI-2 methylation was seven (77.8%) of nine PCa cell lines
by Q-MSP. In cell lines, the expression of TFPI-2 mRNA by quantitative
reverse transcription–polymerase chain reaction showed an inverse
correlation to the aberrant methylation of TFPI-2. The incidence of
aberrant TFPI-2 methylation in the PPJ was 21 (58.3%) of 36 PCa
patients, three (17.6%) of 17 IPMN and one (4.8%) of 21 CP by MSP
assay. Using a suitable cut-off value of 2.5 according to the receiver
operating characteristic curve, the incidence of aberrant TFPI-2
methylation in the PPJ by real-time MSP was 18 (62.1%) of 29 PCa
patients, one (5.1%) of 17 IPMN and three (14.3%) of 21 CP,
respectively. The incidence of quantitative TFPI-2 hypermethylation
in the PPJ with PCa was significantly higher than that with IPMN
(P < 0.001) or CP (P < 0.001). Moreover, the aberrant methylation
rate of TFPI-2 in the PPJ was 100%, as observed (6/6) in the PCa
patients with liver metastasis, and 86.7% (26/30) in stages IVa + IVb
of PCa by Q-MSP assay. These results suggest that promoter
methylation of TFPI-2 in the PPJ may be a useful marker in the
diagnosis and progression of PCa using an endoscopically feasible
approach. (Cancer Sci 2006; 97: 1267–1273)
P ancreatic ductal adenocarcinoma has a poor prognosis withan overall 5-year survival rate ranging from 0.4%(1) to 4%(2);
it is one of the top 10 causes of cancer death in the industrialized
world.(3,4) Even in patients with PCa that underwent curative
surgical resection, the 5-year survival rate was 21% among patients
who received chemotherapy and 8% among patients who did
not receive chemotherapy.(5) This is due both to the inherently
aggressive biology of the disease and to its late diagnosis in most
cases. Today, the diagnostic ability for fairly large PCa has improved
markedly.(6) However, the number of patients with radical resection
of PCa is still small and there are many cases in which
differentiating a malignant lesion of the pancreas from a benign one
is difficult. Although clinical doctors are able to use ultrasound
sonography, computed tomography and endoscopic retrograde
cholangio-pancreatography to characterize early pancreatic
cancer from CP and IPMN, the diagnostic specificity is not sufficient
to differentiate benign and malignant pancreatic tumors when
the pancreatic tumor is small. Difficulty in obtaining a biopsy
specimen in PCa, unlike in gastrointestinal cancer, and the low
diagnostic ability in the cytology of pancreatic juice may be
major factors for such diagnostic difficulty. Recently, the
detection of specific tumor markers in PPJ has become attractive
in the diagnosis of pancreatic diseases.
Based on information obtained from recent molecular bio-
logical studies on carcinogenesis, the activation of oncogenes or
loss of function of tumor suppressor genes (a part of which is
due to aberrant methylation) has been clarified to participate in
tumor development and progression.(6,7) The oncogene K-ras
and tumor suppressor gene p53 have been researched widely all
over the world.(8,9) Although the oncogene and tumor suppressor
gene play a critical role in tumor diagnosis, they are insuffi-
ciently specific or sensitive to improve the diagnosis of PCa.
Recently, aberrant methylations of tumor-related genes are
attractive in the tumor marker investigation. In human cancers,
CpG island methylation occurs aberrantly and is associated with
the inappropriate silencing of tumor suppressor genes and
other genes that function in the suppression of malignant
phenotypes.(10,11) Methylation-mediated silencing contributes to
malignant progression and has been implicated in the inactivation
of genes involved in tumor suppression.
The molecular markers in human PPJ are thought to be accurate
predictors of the early diagnosis of pancreatic disease because
PPJ has a high concentration of DNA, RNA and protein released
from PCa compared with other clinical sources, such as the
serum. We have previously reported the usefulness of analyzing
K-ras and p53 mutations in the supernatant and sediment of PPJ
for the diagnosis of PCa.(12–21) The frequency of K-ras mutations
in PCa tissue ranges from 70% to almost 100%. The incidence
of KRM in PPJ from patients with PCa was over 80% using a
sensitive method, such as mutant allele-specific amplification.
However, KRM was observed in 28% of PPJ from the patients
with CP. Many other studies also reported the frequent presence
(20–30%) of KRM in PPJ from non-cancerous diseases with
conditions such as CP and IPMN, raising questions as to the
cancer specificity of this marker. A qualitative analysis of
KRM in PPJ is unsuitable for definite diagnosis of PCa but is
appropriate for PCa screening. In contrast, a hybridization
protection assay using acridinium ester-labeled DNA probes can
quantitatively determine the KRM in PPJ. Using this method,
quantitative analysis of KRM in PPJ may be useful for differen-
tiating PCa from CP by using a suitable cut-off value. Although
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the frequency of p53 mutations has been reported to be 40–76%
in PCa tissues, in our previous report, p53 mutations were found
in 42% of PPJ sediment from the patients of PCa examined by
PCR-SSCP and direct sequencing, but were not detectable in
PPJ from 16 CP and four adenoma patients, suggesting that
specificity of p53 mutation is very high for PCa. However, the
sensitivity of p53 mutation in PPJ was not so high. Therefore,
such genetic analyses seem to be limited by relatively high false
positives or insufficient sensitivity. Therefore, a new reliable
marker is needed for the diagnosis of PCa.
Tissue factor pathway inhibitor-2, a structural analog of TFPI,
is a 32-kDa Kunitz-type serine proteinase inhibitor that inhibits
plasmin, trypsin, chymotrypsin, cathepsin G and plasma kallikrein,
and has also been shown to reduce tumor invasion and metasta-
sis.(22–26) The human TFPI-2 gene is located on chromosome
7q22 and its promoter contains a CpG island region of 220 bp
that spans exon 1 and three transcription initiation sites. Recom-
binant TFPI-2 inhibits the plasmin-mediated matrigel and the
degradation of ECM in a dose-dependent manner.(23) The amino
terminal sequence and molecular cloning of the cDNA revealed
that TFPI-2 is identical to retinal pigment epithelial cell factor-
1 and placental protein 5.(24) TFPI-2 is expressed abundantly in
full-term placenta and widely in a variety of adult human tissues
such as liver, skeletal, muscle, heart, kidney and pancreas.(25)
TFPI-2 effectively decreases the activation of MMP-1, MMP-3
and MMP-9, and reduces the invasive potential of several tumor
cells including HT-1080 fibrosarcoma cells and urokinase-
charged Hela cells.(26) TFPI-2 mRNA was induced after demeth-
ylation and histone deacetylation inhibition treatment in vitro.(27,28)
Aberrant methylation has been suggested as a possible mecha-
nism for the loss of TFPI-2 expression in tumor cell lines. Steiner
et al. reported that 5-Aza 2′-deoxycytidine/depsipeptide FK228
treatment induced TFPI-2 expression in CALU-6 and H460 lung
cancer cells.(27) TFPI-2 promoter methylation was observed in
20% (1/5) of pulmonary adenocarcinomas, and 100% (7/7) of
esophageal adenocarcinomas. Sato et al. reported that aberrant
methylation of TFPI-2 was detected in 73% of PCa xenografts
and primary PCa.(29) Hypermethylation of TFPI-2 was also detected
in 57% of the PPJ obtained at surgery from PCa patients and
none of the benign pancreatic disorder patients by MSP assay.
Previous studies implied that TFPI-2 is frequently silenced in
carcinoma because of hypermethylation and deacetylation. The
aim of the present study was to analyze the aberrant methylation
of TFPI-2 in PPJ aspirated by an endoscopically feasible
approach from patients with various pancreatic disorders and to
evaluate its tumor marker value in the diagnosis and prognosis
of PCa.
Materials and Methods
Pancreatic caner cell lines. Nine human pancreatic cancer cell
lines were used in this research. The six human PCa cell lines
(KLM-1, PK-45H, PK-59, PK-1, PK-8 and PK-9) were provided
by the Cell Resource Center for Biomedical Research Institute
of Development Aging and Cancer Bank, Tohoku University
(Sendai, Japan). The human PCa cell line Mia-PaCa-2 was provided
by the Cell Bank at the Riken Bioresource Center (Tsukuba,
Ibaragi, Japan). The two human PCa cell lines PANC-1 and BxPC-
3 were purchased from Dainippon Pharmaceutical Company (Osaka,
Japan). PANC-1 and Mia-PaCa-2 were cultured and maintained
in Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum, penicillin G (100 U/mL) and kanamycin sulfate (100 µg/mL).
KLM-1, PK-45H, PK-59, PK-1, PK-8, PK-9 and BxPC-3 cells
were cultured and maintained in RPMI-1640 with 10% fetal
bovine serum, penicillin and kanamycin at 37°C in a 5% CO2,
95% air atmosphere.
Human pancreatic diseases samples. The PPJ samples from 36
patients with PCa, 10 with malignant IPMN, seven with benign
IPMN and 21 with CP were investigated in the present study
(Table 1). The patients were diagnosed and treated at the
Department of Internal Medicine, Cancer Research Institute
Hospital, Kanazawa University and Kanazawa University Hospital,
and its affiliated facilities in Japan from 1993 to 2005. Informed
consent for this study was obtained from all of the patients.
Ultrasound sonography, computed tomography and endoscopic
retrograde cholangio-pancreatography were carried out in all
cases. Diagnosis of the disease was confirmed based on the
results of these modalities and laboratory data, including elevation
of serum tumor markers, such as CA19-9 and CEA. Twenty PCa
tumors were confirmed histologically at the time of operation or
biopsy under endoscopic ultrasonography. The remaining 16
pancreatic tumors, which were not examined histologically, showed
findings compatible with PCa on ultrasound sonography, computed
tomography and endoscopic retrograde cholangio-pancreatography,
and these patients died of PCa within 6–18 months of diagnosis
with a compatible clinical course. As shown in Table 1, the
mean ages of the PCa, malignant IPMN, benign IPMN and CP
groups were 62.7 ± 12.3 years, 68.5 ± 8.2 years, 69.3 ± 6.6 years
and 58.7 ± 13.3 years, respectively. There was no significant
difference in age between the two groups. The staging of PCa
was determined according to various diagnostic modalities or by
operation according to the TNM Classification of Pancreatic
Carcinoma as set out by the International Union Against Cancer.(30)
The diagnosis of IPMN was made according to the classification
of the Armed Forces Institute of Pathology.(31)
The patients with IPMN were divided into two groups: a
malignant group and a benign group. Clinically tentative
definitions of malignant IPMN were required for at least one of
three conditions under various modalities described below: (1)
diameter of the main pancreatic duct more than 7 mm; (2) size
of the cystic lesions more than 30 mm; (3) mural nodule more
than 6 mm in size; or (4) borderline lesion or carcinoma
histologically confirmed with operative materials. However, the
benign IPMN did not satisfy any condition described above or
show hyperplasia and adenoma was confirmed histologically
with surgical materials. Finally, 10 patients were judged as
malignant IPMN (including two with operation) and seven as
benign IPMN (including one with operation). The diagnosis of
CP was based on the clinical diagnostic curative of the Japan
Pancreas Society.(32) The 21 patients with CP were classified as
definite based on the clinical diagnostic curative and were also
followed up over a 12-month period with no clinical detection
of the PCa tumor.
Pure pancreatic juice samples. Pure pancreatic juice was collected
using a duodenal endoscope (JF-10, JF-230, JF-240; Olympus,
Tokyo, Japan) in the fasting state through a cannula inserted into
the orifice of the papilla vater under stimulation with intravenous
secretin (1 unit/kg), as described previously,(8) and stored at −80°C
until use for genetic analysis.
DNA extraction. DNA extraction of PPJ, PCa cell lines, and
primary PCa tissues was carried out using standard methods
with a phenol–chloroform mixture, and precipitated with ethanol.
Table 1. Characterization of enrolled patients with pancreatic diseases
Disease Total no. cases Mean age (years)
Sex 
male Female
PCa 36 62.7 ± 12.3 28 8
Malignant IPMN 10 68.5 ± 8.2 8 2
Benign IPMN 7 69.3 ± 6.6 5 2
CP 21 58.7 ± 13.3 15 6
CP, chronic pancreatitis; IPMN, intraductal papillary mucinous 
neoplasm; PCa, pancreatic adenocarcinoma.
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RNA isolation and real-time RT-PCR. Total RNA was extracted
from PCa cells using a SV Total RNA Isolation System kit
(Promega, Madison, WI, USA). RNA concentrations were
determined using spectrophotometry. RT was carried out using
a PowerScript Reverse Transcriptase kit (Clontech Laboratories,
Palo Alto, CA, USA). First-strand cDNA was synthesized from
8 µg of total RNA at 65°C for 5 min after RT; incubation at
42°C for 60 min activated the reverse transcriptase and the
reaction was terminated with heating at 70°C for 25 min. The
expression of TFPI-2 mRNA in the PC cell lines was carried
out using the LightCycler real-time PCR apparatus (Roche
Diagnostics, Mannheim, Germany) and LightCycler Fast Start
DNA Master SYBR Green I (Roche Diagnostics), as described
by the manufacturer. The primers of TFPI-2 for RT-PCR were
5′-CCAGATGAAGCTACTTGTATG-3′ for the sense primer and
5′-GCACATGCACGTTTGCAATC-3′ for the antisense primer,
in accordance with a previous report.(29) The conditions for the
real-time RT-PCR reactions were denaturation at 95°C for 10 s,
annealing at 63°C for 8 s and elongation at 72°C for 15 s.
Melting curves were obtained using the LightCycler 3.5 program.
Samples with a similar Tm to the standard BxPC-3 cell line
cDNA were judged as a positive result for TFPI-2 mRNA. 18S
was used as an internal control.
Bisulfite modification and MSP. DNA samples were treated with
sodium bisulfite for 16 h at 50°C and purified using a CpGenome
DNA modification kit (Chemicon International, Temecula, CA,
USA). MSP primers for TFPI-2 were designed as: unmethylation
forward, 5′-GGATGTTTGTTTTGTATAAAGTG-3′, and reverse,
5′-AAACATCCAAAAAAACACCTAAC-3′, producing an 89-
bp fragment; methylation forward, 5′-TTTCGTATAAAGCGGG
TATTC-3′, and reverse, 5′-ACGACCCGCTAAACAAAACG-3′,
producing a 95-bp fragment.(29) Each MSP reaction incorporated
1 µg of bisulfite-treated DNA as a template, 10 pmol/L of each
primer, 100 pmol/L deoxynucleoside triphosphate, 10× PCR buffer,
and 1 unit of Taq polymerase in a final reaction volume of 20 µL.
The cycle conditions were as follows: (1) 95°C for 5 min; (2) 35
cycles of 95°C for 20 s, 58°C for 20 s, and 72°C for 30 s; and (3)
72°C for 4 min. Aliquots (8 µL) of MSP products were analyzed
with 3% agarose gel electrophoresis and visualized with SYBR
Gold (Molecular Probes, Eugene, OR, USA) at a 10 000× dilution
in dimethylsulfoxide, and exposed to ultraviolet 312-nm light.
Real-time Q-MSP. Bisulfite-modified DNA (2 µL) was used for
fluorescence-based Q-MSP using the LightCycler real-time
PCR apparatus, and Light Cycler Fast Start DNA Master SYBR
Green I was used as described by the manufacturer. The
methylation-specific primers for TFPI-2 were used in the same
way as for the MSP assay. The conditions for the Q-MSP
reactions were: denaturation at 95°C for 10 s, annealing at 58°C
for 10 s and elongation at 72°C for 4 s. The LightCycler 3.5
program provided by the manufacturer carried out the melting
curve. The samples with similar Tm to the standard PK-9
methylation cDNA were judged as being positive for aberrant
methylation of TFPI-2. For the internal reference gene MYOD1,
the primers were designed to amplify and detect a region of the
gene that is devoid of CpG nucleotides. Thus, amplification of
MYOD1 by quantitative real-time MSP occurs independently of
its methylation status, whereas the amplification of TFPI-2 is
proportional to the degree of cytosine methylation within the
TFPI-2 promoter. The methylation ratio was defined as the ratio
of the fluorescence signal for the real-time Q-MSP of TFPI-2
generated by SYBR Green I, to those of the converted MYOD1
templates that were fully methylated at the primer site.(33) Real-
time Q-MSP primers for MYOD1 were designed as methylation
forward, 5′-CCAACTCCAAATCCCCTCTCTAT-3′, and reverse,
5′-TGATTAATTTAGATTGGGTTTAGAGAAGGA-3′ (gene bank:
AF027148), in accordance with a previous report.(34)
Statistical methods. Experimental results were expressed as
the mean ± SEM. The difference between the means was evaluated
with the Mann–Whitney U-test. P < 0.05 was considered to be
statistically significant. The statistical analysis was carried out
using StatView-5.0 (SAS Institute, Tokyo, Japan).
Results
Expression of TFPI-2 mRNA and aberrant methylation of TFPI-2
in the pancreatic cancer cell lines by quantitative analysis.
Measurement of TFPI-2 mRNA was carried out by quantitative
RT-PCR. Serial 10-fold dilutions of BxPC-3 cDNA were subjected
to real-time RT-PCR to construct standard curves (Fig. 1a). A
positive result was defined as one with the same Tm as for
TFPI-2 cDNA. The Tm of RT-PCR products for TFPI-2 was
83.54°C (data not shown). TFPI-2 mRNA was expressed in
PK-8, KLM-1, Mia-PaCa-2 and BxPC-3 cell lines (Fig. 1c). 18S
was also measured by real-time RT-PCR as an internal control
(data not shown). As shown in Fig. 1b, using a TFPI-2
methylation-specific primer, the aberrant methylation of TFPI-
2 was investigated by real-time MSP. Serial 10-fold dilutions of
PK-9 methylation cDNA were subjected to real-time MSP with
the samples and gave standard curves. The positive results of
samples were assessed according to the Tm of the methylated
TFPI-2 cDNAs. The Tm of hypermethylated TFPI-2 was
82.30°C (data not shown). Expression of aberrantly methylated
TFPI-2 was recognized in all cell lines, except for PK-8 and
PANC-1. MYOD1 acted as an internal control using the same
DNA modified by bisulfite. As shown in Fig. 1c, the ratios of
TFPI-2:18S mRNA and hypermethylated TFPI-2:MYOD1
were calculated. There were four patterns of TFPI-2 expression
and aberrant methylation in the PCa cell lines examined. The
first pattern was TFPI-2 mRNA expression with no aberrant
methylation (PK-8). The second was low expression of TFPI-2
mRNA and aberrant methylation of TFPI-2 (KLM-1, Mia-
PaCa-2 and BxPC-3). The third was expression of aberrantly
methylated TFPI-2, with no TFPI-2 mRNA expression (PK-
45H, PK-59, PK-1 and PK-9). The fourth was neither TFPI-2
mRNA expression nor aberrant methylation of TFPI-2
expression (PANC-1).
Aberrant methylation of TFPI-2 in PPJ of various pancreatic
diseases and primary pancreatic cancer tissues by MSP analysis.
As shown in Fig. 2a, there was aberrant methylation of TFPI-2
in the PPJ obtained endoscopically from the patients with PCa,
IPMN and CP, and primary PCa tissues by MSP using two pairs
of specific PCR primers. The incidences of aberrant methylation
for TFPI-2 in the PPJ from the patients with PCa, IPMN and CP
were 58.3% (21/36), 17.6% (3/17) and 4.8% (1/21), respectively
(Fig. 2b). The incidence of aberrant methylation of TFPI-2 in
PCa was more frequent than that with IPMN or CP. Moreover,
among IPMN, the incidence of hypermethylation of TFPI-2 was
14.3% (1/7) in benign IPMN and 20% (2/10) in malignant
IPMN. According to statistical analysis, the hypermethylation
rate of TFPI-2 in PPJ with PCa was significantly higher than
that with IPMN or CP, respectively (P < 0.01, P < 0.001). However,
there was no significant difference between IPMN and CP. In
addition, there was no significant difference between benign
IPMN and malignant IPMN.
Among 36 patients with PCa, 20 patients were confirmed as
PCa histologically. Twelve of the 20 patients with PCa had
positive results for aberrant methylation of TFPI-2 in the PPJ.
Aberrant methylation of TFPI-2 was recognized in all of the
four available PCa tissue samples examined out of the 12 PCa
patients, as shown in Fig. 2a. Therefore, aberrant methylation of
TFPI-2 was confirmed in the primary PCa tissues examined in
line with the positive results of PPJ.
Aberrant methylation of TFPI-2 in PPJ of various pancreatic
diseases by Q-MSP analysis. Aberrant methylation of TFPI-2 was
measured in the PPJ obtained endoscopically from patients with
PCa, IPMN and CP by Q-MSP. The Tm of hypermethylated
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TFPI-2 was 82.30°C (data not shown). The ratios of hypermethylated
TFPI-2:MYOD1 in the PPJ of PCa, IPMN and CP were
calculated (Fig. 3a). The ranges of the data for PCa, IPMN and
CP were from 0.005 to 27.84, from 0 to 4.5 and from 0 to 6.82,
respectively. The mean ratios of hypermethylated TFPI-
2:MYOD1 in the PPJ of PCa, IPMN and CP were 6.62 ± 7.20,
0.58 ± 1.02 and 1.28 ± 1.73, respectively. However, the mean
ratio of aberrantly methylated TFPI-2:MYOD1 in the PPJ was
0.136 ± 0.07 in benign IPMN and 0.884 ± 0.42 in malignant
IPMN. In addition, it was 4.827 ± 2.191 for the PCa patients
with liver metastasis. The hypermethylation ratio of TFPI-
2:MYOD1 in PCa was significantly higher than that in IPMN
(P < 0.01) or CP (P < 0.05). There was no significant difference
between IPMN and CP. There was also no significant difference
between benign IPMN and malignant IPMN.
To improve the diagnostic accuracy, in accordance with the
receiver operating characteristic curve analysis method, 2.5 was
selected to be a suitable cut-off value in this study (Fig. 3b).
Using this cut-off value, the aberrant methylation of TFPI-2 in
PCa, IPMN and CP was 62.1% (18/29), 5.9% (1/17) and 14.3%
(3/21), respectively (Fig. 3c). The incidence of TFPI-2 methyla-
tion was 0% (0/7) in benign IPMN and 10% (1/10) in malignant
IPMN. The incidence of hypermethylated TFPI-2 in the PPJ of
PCa was significantly higher than that of IPMN (P < 0.001) or
CP (P < 0.001). There was no significant difference between
IPMN and CP. In addition, there was no significant difference
between benign IPMN and malignant IPMN.
Correlation of the aberrant methylation of TFPI-2 in PPJ with the
clinicopathological parameters of pancreatic carcinoma between MSP
and Q-MSP. We evaluated the aberrant methylation of TFPI-2 in
the PPJ aspirated endoscopically by MSP and Q-MSP and
compared the results with the clinicopathological parameters of
PCa (Table 2). The incidence of TFPI-2 hypermethylation was
83.3% (5/6) in stages I + II + III and 53.3% (16/30) in stages
Fig. 1. The amplification curves of tissue factor
pathway inhibitor 2 (TFPI-2) mRNA expression and
TFPI-2 aberrant methylation in the pancreatic cancer
cell lines by quantitative analysis. (a) Serial 10-fold
dilutions of the BxPC-3 cDNA gave the standard
curves. The positive results of samples were judged
according to the same melting temperatures and
similar melting curves as the TFPI-2 cDNAs. TFPI-2
mRNA was expressed in KLM-1, Mia-PaCa-2, PK-8
and BxPC-3 cell lines. (b) Serial 10-fold dilutions of
the PK-9 methylation cDNA gave the standard
curves. The positive results of samples were judged
according to the same melting temperature and a
similar melting curve as the methylated TFPI-2 cDNAs.
The aberrant methylation of TFPI-2 was detected in
KLM-1, Mia-PaCa-2, PK-45H, PK-59, PK-1, PK-9 and
BxPC-3 cell lines. (c) The ratios of TFPI-2:18S mRNA
and hypermethylated TFPI-2:MYOD1 in pancreatic
cancer cell lines were compared. The expression of
TFPI-2 mRNA showed an inverse correlation to the
aberrant methylation of TFPI-2 by real-time analysis.
Table 2. Comparison of clinicopathological factors with pancreatic
carcinoma patients for aberrant methylation of tissue factor pathway
inhibitor 2 (TFPI-2) in pure pancreatic juice
Clinicopathological factor
MSP positive Q-MSP positive 
n % n %
Clinical stage
I + II + III 5/6 83.3 3/6 50.0
IVa + IVb 16/30 53.3 26/30 86.7
TS
1 +2 + 3 19/33 57.6 27/33 81.8
4 2/3 66.7 2/3 66.7
Location
H 11/16 68.8 14/16 87.5
B 10/16 62.5 13/16 87.5
T 0/4 0 2/4 50.0
Histological type
G1 3/4 75.0 4/4 100
G2 6/11 54.5 6/11 54.5
G3 2/6 33.3 6/6 100
Live metastasis age (years)†
<50 2/3 66.7 3/3 100
50 ≤ 60 7/12 58.3 8/12 66.7
60 ≤ 70 4/8 50 8/8 100
≥70 8/13 61.5 10/13 76.9
†Quantitative MSP (Q-MSP) for liver metastasis versus methylation-
specific polymerase chain reaction (MSP) for liver metastasis (P < 0.05). 
No P-values were significant. B, body; G1, well-differentiated; G2, 
moderately differentiated; G3, poorly differentiated; H, head; T, tail; 
TS, tumor size.
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IVa + IVb by MSP, whereas it was 50% (3/6) in stages I
+ II + III and 86.7% (26/30) in stages IVa + IVb by Q-MSP. There
was no significant difference between stages I + II + III and stages
IVa + IVb. However, the aberrant methylation of TFPI-2 in the
PPJ from the PCa patients with liver metastasis was extremely
high (up to 100% [6/6]) by Q-MSP. The sensitivity, specificity
and efficiency of liver metastasis with TFPI-2 methylation were
33.3%, 35.7% and 35.3% by MSP, whereas they were 100%,
27.6% and 40.0% by Q-MSP. Q-MSP was better than MSP
for detecting liver metastasis (P < 0.05). In contrast, there was
no significant difference between TFPI-2 hypermethylation
by MSP and Q-MSP assay, and tumor size, tumor location,
histological type or age, respectively.
Discussion
We have shown aberrant methylation in the promoter region of
TFPI-2 in various pancreatic diseases and PCa cell lines. A
relative decrease of TFPI-2 mRNA synthesis was demonstrated
in this study in 44.4% of PCa cell lines using a real-time RT-
PCR assay. Real-time RT-PCR is a sensitive and reproducible
method, compared with Northern blot analysis, semiquantitative
RT-PCR and competitive RT-PCR. There were four patterns for
the expression of TFPI-2 mRNA and hypermethylated TFPI-2
in the PCa cell lines examined. The expression of TFPI-2 mRNA
was inversely proportional to that of aberrantly methylated TFPI-2
in most of the PCa cell lines examined. These results suggest that
hypermethylation of TFPI-2 is involved in silencing TFPI-2
mRNA in the PCa cell lines. However, neither TFPI-2 mRNA
nor hypermethylated TFPI-2 was detected in the PANC-1 cell
line. These findings suggest that besides methylation, there were
other mechanisms involved in silencing TFPI-2 mRNA in the
Fig. 2. Detection of the aberrant methylation of tissue factor pathway
inhibitor 2 (TFPI-2) in pure pancreatic juice (PPJ) from the patients with
pancreatic adenocarcinoma (PCa), intraductal papillary mucinous
neoplasm (IPMN) and chronic pancreatitis (CP), and primary PCa tissues
by methylation-specific polymerase chain reaction (MSP) analysis. (a)
Using methylation and unmethylation specific primers, the 95-bp methylated
PCR product and 89-bp unmethylated PCR product were detected in
the PPJ from patients with PCa, IPMN and CP, and primary PCa tissues.
(b) The aberrant methylation rate of TFPI-2 in PCa, IPMN and CP was
58.3% (21/36), 17.6% (3/17) and 4.8% (1/21), respectively. The
hypermethylation rate of TFPI-2 was 14.3% (1/7) in benign IPMN and
20% (2/10) in malignant IPMN. The hypermethylation rate of TFPI-2
in PCa was significantly higher than that in IPMN or CP, respectively
(P < 0.01, P < 0.001).
Fig. 3. Aberrant methylation of tissue factor pathway inhibitor 2
(TFPI-2) in pure pancreatic juice (PPJ) from patients with pancreatic
adenocarcinoma (PCa), intraductal papillary mucinous neoplasm (IPMN)
and chronic pancreatitis (CP) by real-time methylation-specific
polymerase chain reaction (MSP) analysis. (a) The ratio of hypermethy-
lated TFPI-2:MYOD1 in PCa, IPMN and CP was 6.62 ± 7.20, 0.58 ± 1.02
and 1.28 ± 1.73, respectively. The hypermethylation in PCa was sig-
nificantly higher than that in IPMN (P < 0.01) or CP (P < 0.05). There was
no significant difference between IPMN and CP. (b) The receiver
operating characteristic curve of TFPI-2 methylation in PCa diagnosis
from the other pancreatic diseases. The suitable cut-off value was
selected as 2.5. FPR, false positive rate; TPR, true positive rate. (c) Using
2.5 as a suitable cut-off value, the aberrant methylation rates of TFPI-
2 in PCa, IPMN and CP was 62.1% (18/29), 5.9% (1/17) and 14.3%
(3/21), respectively. The incidence of hypermethylation for TFPI-2 in PCa
was significantly higher than that in IPMN (P < 0.001) or CP (P < 0.001).
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PANC-1 cell line. Besides aberrant methylation, there are many
mechanisms involved in silencing tumor genes, such as deletion,
mutation, histone deacetylation and phosphorylation. It is
known that the mechanisms of TFPI-2 silencing are related to
hypermethylation, histone deacetylation and the Ras/Raf/MEK/
ERK pathway.(27,35–37)
Characterization of the tumor-related genes silenced or activated
by aberrant methylation and their roles in human tumorigenesis
may afford significant insight into the peculiar biology associated
with PCa. The aberrant methylation of TFPI-2 was detected in
PPJ from patients with the PCa, IPMN and CP. The hypermethylation
of TFPI-2 in PCa was significantly higher than that in IPMN or
CP according to both MSP and Q-MSP assays. These results
suggest that the aberrant methylation of TFPI-2 is actually
involved in PCa development and progression, and is related to
the silencing of TFPI-2 mRNA expression. Because the MSP
results for TFPI-2 hypermethylation in PCa were significantly
higher than those in IPMN and CP, the MSP assay can be useful
in the diagnosis of PCa. The aberrant methylation of TFPI-2 in
PCa by real-time MSP assay was not significantly higher than
that by MSP analysis.
Tissue factor pathway inhibitor 2 suppresses the degradation
of ECM and reduces tumor invasion as a serine proteinase
inhibitor. Silencing TFPI-2 causes the loss of its original functions.
Rollin et al. reported that decreased TFPI-2 gene expression and
TFPI-2 hypermethylation are more frequently associated with
advanced stages of non-small cell lung cancer, and that the TFPI-2
gene promoter is more frequently hypermethylated in patients
with lymph node metastases.(38) However, Konduri et al. showed
that TFPI-2 mRNA is more highly expressed in low-grade gliomas
than in high-grade gliomas.(35,37) We showed that the aberrant
methylation rate of TFPI-2 in the PPJ was 100% (6/6), as
observed in PCa patients with liver metastasis, and 86.7%
(26/30) in stages IVa + IVb of PCa by Q-MSP assay. The
hypermethylation of TFPI-2 in the PPJ is thought to be one of
the most sensitive markers in the diagnosis of liver metastasis
from PCa. It may be used as a predictor of cancer progression
and to speculate about prognosis using an endoscopically
feasible approach.
There are many hypermethylated genes involved in the course
of PCa development, such as SARP2, ppENK, cyclin D2, NTPX2
and CLDN5.(11,39–41) The incidence of aberrant promoter
methylation of Cyclin D2 in PCa and IPMN was 65.1% (71/
109) and 50% (23/46), respectively.(40) The hypermethylation of
SARP2, NTPX2 and CLDN5 in PCa, IPMN and CP was 75%,
85% and 5%, 71%, 53% and 32%, and 26%, 47% and 16%,
respectively (unpublished data). Compared with these genes, the
aberrant methylation of TFPI-2 is more specific to PCa. Sato
et al. reported that the hypermethylated TFPI-2 was detected in
57% of PPJ obtained at operation of PCa patients, and in 0% of
benign pancreatic disorder patients.(39) Therefore, the detection
of aberrantly methylated TFPI-2 in PPJ may be used in the diagnosis
of PCa, especially in the differential diagnosis of benign and
malignant pancreatic diseases.
Intraductal papillary mucinous neoplasm showed a broad
spectrum of cytological and architectural atypia, ranging from
benign (hyperplasia and adenoma) to malignant (carcinoma),
and may be considered as a precancerous lesion. In the present
study, IPMN was divided into benign and malignant groups under
diagnostic criteria. Although our data showed that the aberrant
methylation rate of TFPI-2 in malignant IPMN was slightly
higher than that in benign IPMN, there was no significant differ-
ence between them (Fig. 2b). In contrast, Sato et al.(29) divided
IPMN into two groups according to histological grade: those
classified as adenoma and borderline (low-grade IPMN) and
those classified as in situ carcinoma (high-grade IPMN). This
classification of IPMN was not different from ours. High-grade
IPMN were nearly IPMN-derived carcinoma. They reported that
aberrant methylation of TFPI-2 was detected at a significantly
higher frequency in high-grade IPMN than in low-grade IPMN
(85% vs 17%: P = 0.0002) by MSP. In our study, low incidence
of TFPI-2 methylation in the PPJ from both benign and malignant
IPMN groups by both MSP and Q-MSP suggests that the cause
of the low incidence of TFPI-2 methylation was that no IPMC
manifested histologically in the malignant IPMN group. Moreover,
the aberrant methylation rate of TFPI-2 in the PPJ was 100% (6/
6) in the PCa patients with liver metastasis, and 86.7% (26/30)
in stage IVa + IVb of PCa by Q-MSP. These results indicate that
aberrant methylation of TFPI-2 may be specific to PCa and later
events in the progression of PCa.
In the present study, we compared the clinical usefulness of
aberrant methylation of TFPI-2 in the PPJ for the diagnosis of
PCa for between MSP and Q-MSP. Using the MYOD1 gene as
an internal reference, 2.5 was selected as a suitable cut-off value
for the ratio of TFPI-2:MYOD1 under receiver operator charac-
teristic curve analysis with Q-MSP. The incidence of TFPI-2
hypermethylation was 83.3% in stages I–III and 53.3% in stage
IV by MSP, whereas it was 50% in stages I–III and 86.7% in
stage IV by Q-MSP. There was no statistical significance between
MSP and Q-MSP. These results suggest that Q-MSP was not
always superior to MSP for clinical utility in the diagnosis and
progression of PCa. In addition, the MSP method for the aberrant
methylation of TFPI-2 in the PPJ was simple and convenient
and useful for the diagnosis of PCa.
In conclusion, we have shown that hypermethylation of TFPI-
2 in the PPJ was detected in 58.3% (21/36) of PCa, 17.6% (3/
17) of IPMN and 4.8% (1/21) of CP by MSP assay. The hyper-
methylation of TFPI-2 was higher in liver metastasis patients
according to Q-MSP assay. Detection of the aberrant methylation
of TFPI-2 in PPJ may be useful in the diagnosis of PCa, especially
in the differential diagnosis of benign and malignant pancreatic
diseases, and in the progression of PCa using an endoscopically
feasible approach.
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